The roots of the Duke Human Vaccine Institute (DHVI) began in 1985. Soon after the discovery of the human immunodeficiency virus (HIV), a working group was formed at Duke University to make a vaccine for AIDS. In 1990, the Duke Human Vaccine Institute, located in
Durham, North Carolina, was formed to support
Duke University School of Medicine's interdisciplinary efforts to develop
vaccines and
therapeutics for
HIV and other emerging infections. DHVI received support from the Dean of the School of Medicine to recruit new faculty for HIV research and to apply for a Regional Center for Excellence in Emerging Infections and Biodefense grant from the
National Institutes of Health (NIH) in 2002. In 2003, the NIH funded the construction of the Duke Global Health Research Building, an
infectious disease research facility and a Regional Biocontainment Laboratory (RBL). Completed in 2006, this building is designed to support basic research and to provide
surge capacity in the event of a
public health emergency. In 2005, DHVI became the home to the
NIAID-funded Center for HIV/AIDS Vaccine Immunology; a $350 million grant to speed the development of an AIDS vaccine was made. This was led by
Barton Haynes. Over the next 7 years (beginning in 2012), the Duke CHAVI-ID builds on CHAVI to improve
HIV-1 vaccine design. ==References==